Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities reported modest gains in the fourth quarter of 2025. The quarter started as a continuation of the post-Liberation Day risk-on market environment, while it ended on a strong note, driven by a positive macroeconomic backdrop. Attractive valuations, earnings recovery, broadening of the market, and a shift from mega-cap stocks supported small caps in the quarter. The Aristotle Small Cap Equity Fund (Class I-2) returned 1.96% in Q4 2025, trailing the 2.19% total return of the Russell 2000 Index. Security selection supported overall performance, while allocation effects detracted from performance. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Aristotle Small Cap Equity Fund highlighted AptarGroup, Inc. (NYSE:ATR) as a recent addition to its portfolio. AptarGroup, Inc. (NYSE:ATR) is a leading healthcare company that focuses on drug delivery, consumer product dispensing, and active material science solutions and services. On February 13, 2026, AptarGroup, Inc. (NYSE:ATR) stock closed at $142.58 per share. One-month return of AptarGroup, Inc. (NYSE:ATR) was 14.33%, and its shares are down 1.53% over the past twelve months. AptarGroup, Inc. (NYSE:ATR) has a market capitalization of $9.356 billion.
Aristotle Small Cap Equity Fund stated the following regarding AptarGroup, Inc. (NYSE:ATR) in its fourth quarter 2025 investor letter:
“AptarGroup, Inc. (NYSE:ATR) is a global packaging company focused on the design and manufacturing of dosing, dispensing, and protection technologies, serving multiple industries, including pharmaceutical, beauty, personal care, home care, and food and beverage. A combination of a cyclical rebound in demand plus the growth and financial benefits of the company’s continued investment in its pharmaceutical products division should position the company to create shareholder value over the next several years.”
AptarGroup, Inc. (NYSE:ATR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 29 hedge fund portfolios held AptarGroup, Inc. (NYSE:ATR) at the end of the third quarter, the same as in the previous quarter. In the fourth quarter ended December 31,2025, AptarGroup, Inc.’s (NYSE:ATR) reported sales increased 14% to $963 million. While we acknowledge the risk and potential of AptarGroup, Inc. (NYSE:ATR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AptarGroup, Inc. (NYSE:ATR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered AptarGroup, Inc. (NYSE:ATR) and shared Ave Maria Growth Fund’s views on the company last quarter. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
